Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Gastroenterology Reports
Published in: Current Gastroenterology Reports 10/2014

01-10-2014 | Nutrition and Obesity (S McClave, Section Editor)

When Can Nutritional Therapy Impact Liver Disease?

Authors: Matthew C. Bozeman, Matthew V. Benns, Stephen A. McClave, Keith R. Miller, Christopher M. Jones

Published in: Current Gastroenterology Reports | Issue 10/2014

Login to get access

Abstract

This article reviews the current literature regarding nutritional therapy in liver disease, with an emphasis on patients progressing to liver failure as well as surgical patients. Mechanisms of malnutrition and sarcopenia in liver failure patients as well as nutritional assessment, nutritional requirements of this patient population, and goals and methods of therapy are discussed. Additionally, recommendations for feeding, micronutrient, branched chain amino acid supplementation, and the use of pre- and probiotics are included. The impact of these methods can have on patients with advanced disease and those undergoing surgical procedures will be emphasized.
Literature
1.
O’Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342:273–5.PubMedCrossRef
2.
Caregaro L, Alberino F, Amodio P, et al. Malnutrition in alcoholic and virus-related cirrhosis. Am J Clin Nutr. 1996;63:602–9.PubMed
3.
Dudrick SJ, Kavic SM. Hepatobiliary nutrition: history and future. J Hepatobiliary Pancreat Surg. 2002;9:459–68.PubMedCrossRef
4.
Italian Multicentre Cooperative Project on Nutrition in Liver Cirrhosis. Nutritional status in cirrhosis. J Hepatol. 1994;21:317–25.CrossRef
5.
Carvalho L, Parise ER. Evaluation of nutritional status of nonhospitalized patients with liver cirrhosis. Arq Gastroenterol. 2006;43:269–74.PubMedCrossRef
6.
Altamirano J, Fagundes C, Dominguez M, et al. Acute kidney injury is an early predictor of mortality for patients with alcoholic hepatitis. Clin Gastroenterol Hepatol. 2012;10:65–71.PubMedCrossRef
7.
Tan BH, Birdsell LA, Martin L, et al. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res. 2009;15:6973–9.PubMedCrossRef
8.
van Vledder MG, Levolger S, Ayez N, et al. Body composition and outcome in patients undergoing resection of colorectal liver metastases. Br J Surg. 2012;99:550–7.PubMedCrossRef
9.
Sabel MS, Lee J, Cai S, et al. Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann Surg Oncol. 2011;18:3579–85.PubMedCrossRef
10.•
Montano-Loza AJ, Meza-Junco J, Prado CM, et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol. 2012;10:166–73. This study demonstrated only a very low level of association between scoring systems for liver disease and sarcopenia, as measured by CT scan at the third vertebral level. Length of survival and mortality were worse in patients with sarcopenia. A question raised by this study is whether sarcopenia should be included in conventional models of liver disease.PubMedCrossRef
11.
12.
Rosenberg I. Summary comments: epidemiological and methodological problems in determining nutritional status in older persons. Am J Clin Nutr. 1989;50:1231–3.
13.
Delmonico MJ, Harris TB, Lee JS, et al. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc. 2007;55:769–74.PubMedCrossRef
14.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39:412–23.PubMedCrossRefPubMedCentral
15.
Goodpaster BH, Park SW, Harris TB, et al. The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci. 2006;61:1059–64.PubMedCrossRef
16.
Rosenberg I. Sarcopenia: origins and clinical relevance. J Nutr. 1997;127:990S–1S.PubMed
17.
Figueiredo FA, Dickson ER, Pasha TM, et al. Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease. Liver Transpl. 2000;6:575–81.PubMedCrossRef
18.
Sam J, Nguyen GC. Protein-calorie malnutrition as a prognostic indicator of mortality among patients hospitalized with cirrhosis and portal hypertension. Liver Int. 2009;29:1396–402.PubMedCrossRef
19.
Thuluvath PJ, Triger DR. Evaluation of nutritional status by using anthropometry in adults with alcoholic and nonalcoholic liver disease. Am J Clin Nutr. 1994;60:269–73.PubMed
20.
Morgan MY, Madden AM, Jennings G, et al. Two-component models are of limited value for the assessment of body composition in patients with cirrhosis. Am J Clin Nutr. 2006;84:1151–62.PubMed
21.
Morgan MY, Madden AM, Soulsby CT, et al. Derivation and validation of a new global method for assessing nutritional status in patients with cirrhosis. Hepatology. 2006;44:823–35.PubMedCrossRef
22.
Mourtzakis M, Prado CM, Lieffers JR, et al. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab. 2008;33:997–1006.PubMedCrossRef
23.
Norman K, Stobaus N, Pirlich M, et al. Bioelectrical phase angle and impedance vector analysis—clinical relevance and applicability of impedance parameters. Clin Nutr. 2012;31:854–61.PubMedCrossRef
24.•
Tandon P, Ney M, Irwin I, et al. Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl. 2012;18:1209–16. A well done study describing the incidence of sarcopenia in the pre-transplant patient population which could serve as a model for future research into the role sarcopenia should play in determining organ allocation.PubMedCrossRef
25.
Krell RW, Kaul DR, Martin AR, et al. Association between sarcopenia and the risk of serious infection among adults undergoing liver transplantation. Liver Transpl. 2013;19:1396–402.PubMedCrossRef
26.
Alvares-da-Silva MR, Reverbel da Silveira T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. Nutrition. 2005;21:113–7.PubMedCrossRef
27.
Juakiem W, Torres DM, Harrison SA. Nutrition in cirrhosis and chronic liver disease. Clin Liver Dis. 2014;18:179–90.PubMedCrossRef
28.
Mathan LKE-SS. Krause’s food nutrition and diet therapy. Philadelphia: WB Saunders; 2000.
29.
Plauth M, Cabre E, Riggio O, et al. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr. 2006;25:285–94.PubMedCrossRef
30.
Hasse J, Strong S, Gorman MA, et al. Subjective global assessment: alternative nutrition-assessment technique for liver-transplant candidates. Nutrition. 1993;9:339–43.PubMed
31.
32.
Aqel BA, Scolapio JS, Dickson RC, et al. Contribution of ascites to impaired gastric function and nutritional intake in patients with cirrhosis and ascites. Clin Gastroenterol Hepatol. 2005;3:1095–100.PubMedCrossRef
33.
34.
Cheung K, Lee SS, Raman M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. Clin Gastroenterol Hepatol. 2012;10:117–25.PubMedCrossRef
35.
Tsiaousi ET, Hatzitolios AI, Trygonis SK, et al. Malnutrition in end stage liver disease: recommendations and nutritional support. J Gastroenterol Hepatol. 2008;23:527–33.PubMedCrossRef
36.
Vlahcevic ZR, Buhac I, Farrar JT, et al. Bile acid metabolism in patients with cirrhosis. I. Kinetic aspects of cholic acid metabolism. Gastroenterology. 1971;60:491–8.PubMed
37.
Dam G, Ott P, Aagaard NK, et al. Branched-chain amino acids and muscle ammonia detoxification in cirrhosis. Metab Brain Dis. 2013;28:217–20.PubMedCrossRef
38.
American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors. Clinical guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients, 2009. JPEN J Parenter Enteral Nutr. 2009;33:255–9.CrossRef
39.
Tsien CD, McCullough AJ, Dasarathy S. Late evening snack: exploiting a period of anabolic opportunity in cirrhosis. J Gastroenterol Hepatol. 2012;27:430–41.PubMedCrossRef
40.
Vaisman N, Katzman H, Carmiel-Haggai M, et al. Breakfast improves cognitive function in cirrhotic patients with cognitive impairment. Am J Clin Nutr. 2010;92:137–40.PubMedCrossRef
41.
Matos C, Porayko MK, Francisco-Ziller N, et al. Nutrition and chronic liver disease. J Clin Gastroenterol. 2002;35:391–7.PubMedCrossRef
42.
43.
Pescovitz MD, Mehta PL, Jindal RM, et al. Zinc deficiency and its repletion following liver transplantation in humans. Clin Transplant. 1996;10:256–60.PubMed
44.
Munoz SJ, Deems RO, Moritz MJ, et al. Hyperlipidemia and obesity after orthotopic liver transplantation. Transplant Proc. 1991;23:1480–3.PubMed
45.
Janczewska I, Ericzon BG, Eriksson LS. Influence of orthotopic liver transplantation on serum vitamin A levels in patients with chronic liver disease. Scand J Gastroenterol. 1995;30:68–71.PubMedCrossRef
46.
Ozaki N, Ringe B, Gubernatis G, et al. Changes in energy substrates in relation to arterial ketone body ratio after human orthotopic liver transplantation. Surgery. 1993;113:403–9.PubMed
47.
Palmer M, Schaffner F, Thung SN. Excessive weight gain after liver transplantation. Transplantation. 1991;51:797–800.PubMedCrossRef
48.
Holt RI, Broide E, Buchanan CR, et al. Orthotopic liver transplantation reverses the adverse nutritional changes of end-stage liver disease in children. Am J Clin Nutr. 1997;65:534–42.PubMed
49.
Canzanello VJ, Schwartz L, Taler SJ, et al. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg. 1997;3:1–9.PubMedCrossRef
50.
Hasse J. Liver transplantation: the benefits of nutrition therapy in the liver transplant patient. Liver Transpl. 1996;2:81–100.
51.
Shanbhogue RL, Bistrian BR, Jenkins RL, et al. Increased protein catabolism without hypermetabolism after human orthotopic liver transplantation. Surgery. 1987;101:146–9.PubMed
52.•
Kaido T, Ogawa K, Fujimoto Y, et al. Impact of sarcopenia on survival in patients undergoing living donor liver transplantation. Am J Transplant. 2013;13:1549–56. This work investigated the impact of sarcopenia and immunonutrition in liver transplant patients. Lean muscle mass was evaluated prior to transplant by BIA, and patients were fed immunomodulating formulas early in the perioperative period. Low lean muscle mass was independently associated with mortality, but the addition of early immunomodulating enteral feeds increased survival in patients with low skeletal mass. These results could allow for improved recipient selection, as well as illustrates the impact immunonutrition could play in these complex patients.PubMedCrossRef
53.
Kaido T, Mori A, Ogura Y, et al. Impact of enteral nutrition using a new immuno-modulating diet after liver transplantation. Hepatogastroenterology. 2010;57:1522–5.PubMed
54.
Kaido T, Mori A, Oike F, et al. Impact of pretransplant nutritional status in patients undergoing liver transplantation. Hepatogastroenterology. 2010;57:1489–92.PubMed
55.
Bode JC, Hanisch P, Henning H, et al. Hepatic zinc content in patients with various stages of alcoholic liver disease and in patients with chronic active and chronic persistent hepatitis. Hepatology. 1988;8:1605–9.PubMedCrossRef
56.
Hayashi M, Ikezawa K, Ono A, et al. Evaluation of the effects of combination therapy with branched-chain amino acid and zinc supplements on nitrogen metabolism in liver cirrhosis. Hepatol Res. 2007;37:615–9.PubMedCrossRef
57.
Takuma Y, Nouso K, Makino Y, et al. Clinical trial: oral zinc in hepatic encephalopathy. Aliment Pharmacol Ther. 2010;32:1080–90.PubMedCrossRef
58.
Loser C, Folsch UR. Guidelines for treatment with percutaneous endoscopic gastrostomy. German Society of Digestive and Metabolic Diseases. Z Gastroenterol. 1996;34:404–8.PubMed
59.
Plank LD, McCall JL, Gane EJ, et al. Pre- and postoperative immunonutrition in patients undergoing liver transplantation: a pilot study of safety and efficacy. Clin Nutr. 2005;24:288–96.PubMedCrossRef
60.
Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst Rev. 2004;2, CD003044.PubMed
61.
Agrawal A, Sharma BC, Sharma P, et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol. 2012;107:1043–50.PubMedCrossRef
62.
Amodio P, Bemeur C, Butterworth R, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58:325–36.PubMedCrossRef
63.
McGee RG, Bakens A, Wiley K et al. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev 2011;CD008716.
64.
Holecek M. Three targets of branched-chain amino acid supplementation in the treatment of liver disease. Nutrition. 2010;26:482–90.PubMedCrossRef
65.
Paul HS, Adibi SA. Activation of hepatic branched chain alpha-keto acid dehydrogenase by a skeletal muscle factor. J Biol Chem. 1982;257:12581–8.PubMed
66.
Damuni Z, Merryfield ML, Humphreys JS, et al. Purification and properties of branched-chain alpha-keto acid dehydrogenase phosphatase from bovine kidney. Proc Natl Acad Sci U S A. 1984;81:4335–8.PubMedCrossRefPubMedCentral
67.
Rose CF. Ammonia-lowering strategies for the treatment of hepatic encephalopathy. Clin Pharmacol Ther. 2012;92:321–31.PubMedCrossRef
68.
69.
Yamamoto M, Iwasa M, Matsumura K, et al. Improvement of regional cerebral blood flow after oral intake of branched-chain amino acids in patients with cirrhosis. World J Gastroenterol. 2005;11:6792–9.PubMed
70.
Marchesini G, Bianchi G, Merli M, et al. Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology. 2003;124:1792–801.PubMedCrossRef
71.
Muto Y, Sato S, Watanabe A, et al. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis. Clin Gastroenterol Hepatol. 2005;3:705–13.PubMedCrossRef
72.
Nakaya Y, Okita K, Suzuki K, et al. BCAA-enriched snack improves nutritional state of cirrhosis. Nutrition. 2007;23:113–20.PubMedCrossRef
73.
Metadata
Title
When Can Nutritional Therapy Impact Liver Disease?
Authors
Matthew C. Bozeman
Matthew V. Benns
Stephen A. McClave
Keith R. Miller
Christopher M. Jones
Publication date
01-10-2014
Publisher
Springer US
Published in
Current Gastroenterology Reports / Issue 10/2014
Print ISSN: 1522-8037
Electronic ISSN: 1534-312X
DOI
https://doi.org/10.1007/s11894-014-0411-3

Other articles of this Issue 10/2014

Current Gastroenterology Reports 10/2014 Go to the issue

Pancreas and Biliary Tract (O Haluszka, Section Editor)

The Treatment of Cholangiocarcinoma: a Hepatologist’s Perspective

Large Intestine (B Cash, Section Editor)

Narcotic Bowel Syndrome and Opioid-Induced Constipation

Nutrition and Obesity (S McClave, Section Editor)

Tips and Tricks for Deep Jejunal Enteral Access: Modifying Techniques to Maximize Success

Large Intestine (B Cash, Section Editor)

Common Anorectal Conditions: Evaluation and Treatment

Large Intestine (B Cash, Section Editor)

Health Maintenance and Inflammatory Bowel Disease

Stomach and Duodenum (J Pisegna, Section Editor)

Endoscopic Management of Bleeding Gastric Varices—an Updated Overview
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits